{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T07:36:50Z","timestamp":1767857810610,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,7,23]],"date-time":"2013-07-23T00:00:00Z","timestamp":1374537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,7,23]],"date-time":"2013-07-23T00:00:00Z","timestamp":1374537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s12185-013-1398-5","type":"journal-article","created":{"date-parts":[[2013,7,22]],"date-time":"2013-07-22T18:54:36Z","timestamp":1374519276000},"page":"361-365","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Nilotinib-induced interstitial lung disease"],"prefix":"10.1007","volume":"98","author":[{"given":"Se-Il","family":"Go","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Sup","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyeong-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Hun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung Hee","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoon-Gu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,23]]},"reference":[{"key":"1398_CR1","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","volume":"117","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117:1141\u20135.","journal-title":"Blood"},{"key":"1398_CR2","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251\u20139.","journal-title":"N Engl J Med"},{"key":"1398_CR3","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12:841\u201351.","journal-title":"Lancet Oncol."},{"key":"1398_CR4","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1164\/rccm.200705-715CR","volume":"176","author":"A Bergeron","year":"2007","unstructured":"Bergeron A, Rea D, Levy V, Picard C, Meignin V, Tamburini J, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med. 2007;176:814\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"1398_CR5","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1080\/10428190600555868","volume":"47","author":"F Radaelli","year":"2006","unstructured":"Radaelli F, Bramanti S, Fantini NN, Fabio G, Greco I, Lambertenghi-Deliliers G. Dasatinib-related alveolar pneumonia responsive to corticosteroids. Leuk Lymphoma. 2006;47:1180\u20131.","journal-title":"Leuk Lymphoma"},{"key":"1398_CR6","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260\u201370.","journal-title":"N Engl J Med"},{"key":"1398_CR7","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531\u201341.","journal-title":"N Engl J Med"},{"key":"1398_CR8","first-page":"89","volume":"3","author":"R Swords","year":"2009","unstructured":"Swords R, Mahalingam D, Padmanabhan S, Carew J, Giles F. Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther. 2009;3:89\u2013101.","journal-title":"Drug Des Devel Ther."},{"key":"1398_CR9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3109\/10428194.2011.606940","volume":"53","author":"T Delomas","year":"2012","unstructured":"Delomas T, Darne C, Besson C. Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib. Leuk Lymphoma. 2012;53:332\u20133.","journal-title":"Leuk Lymphoma"},{"key":"1398_CR10","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/sj.leu.2404207","volume":"20","author":"K Ohnishi","year":"2006","unstructured":"Ohnishi K, Sakai F, Kudoh S, Ohno R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia. 2006;20:1162\u20134.","journal-title":"Leukemia"},{"key":"1398_CR11","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.4065\/78.12.1578","volume":"78","author":"CX Ma","year":"2003","unstructured":"Ma CX, Hobday TJ, Jett JR. Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin Proc. 2003;78:1578\u20139.","journal-title":"Mayo Clin Proc"},{"key":"1398_CR12","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1200\/JCO.2003.03.037","volume":"21","author":"MF Rosado","year":"2003","unstructured":"Rosado MF, Donna E, Ahn YS. Challenging problems in advanced malignancy: case 3, imatinib mesylate-induced interstitial pneumonitis. J Clin Oncol. 2003;21:3171\u20133.","journal-title":"J Clin Oncol"},{"key":"1398_CR13","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1159\/000091272","volume":"75","author":"H Yamasawa","year":"2008","unstructured":"Yamasawa H, Sugiyama Y, Bando M, Ohno S. Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis. Respiration. 2008;75:350\u20134.","journal-title":"Respiration."},{"key":"1398_CR14","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","volume":"25","author":"A Quintas-Cardama","year":"2007","unstructured":"Quintas-Cardama A, Kantarjian H, O\u2019Brien S, Borthakur G, Bruzzi J, Munden R, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25:3908\u201314.","journal-title":"J Clin Oncol"},{"key":"1398_CR15","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","volume":"109","author":"H Kantarjian","year":"2007","unstructured":"Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007;109:5143\u201350.","journal-title":"Blood"},{"key":"1398_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/ajh.20319","volume":"79","author":"J Rajda","year":"2005","unstructured":"Rajda J, Phatak PD. Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy. Am J Hematol. 2005;79:80\u20131.","journal-title":"Am J Hematol"},{"key":"1398_CR17","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/S0002-9343(03)00445-5","volume":"115","author":"U Wagner","year":"2003","unstructured":"Wagner U, Staats P, Moll R, Feek U, Vogelmeier C, Groneberg DA. Imatinib-associated pulmonary alveolar proteinosis. Am J Med. 2003;115:674.","journal-title":"Am J Med"},{"key":"1398_CR18","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO.2002.99.179","volume":"20","author":"A Bergeron","year":"2002","unstructured":"Bergeron A, Bergot E, Vilela G, Ades L, Devergie A, Esperou H, et al. Hypersensitivity pneumonitis related to imatinib mesylate. J Clin Oncol. 2002;20:4271\u20132.","journal-title":"J Clin Oncol"},{"key":"1398_CR19","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1080\/10428190600625216","volume":"47","author":"JT Lin","year":"2006","unstructured":"Lin JT, Yeh KT, Fang HY, Chang CS. Fulminant, but reversible interstitial pneumonitis associated with imatinib mesylate. Leuk Lymphoma. 2006;47:1693\u20135.","journal-title":"Leuk Lymphoma"},{"key":"1398_CR20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1445-5994.2004.00757.x","volume":"35","author":"P Grimison","year":"2005","unstructured":"Grimison P, Goldstein D, Schneeweiss J, Murray N. Corticosteroid-responsive interstitial pneumonitis related to imantinib mesylate with successful rechallenge, and potential causative mechanisms. Intern Med J. 2005;35:136\u20137.","journal-title":"Intern Med J."},{"key":"1398_CR21","first-page":"918","volume":"47","author":"N Izumiyama","year":"2009","unstructured":"Izumiyama N, Noguchi K, Takahashi H, Shishikura Y, Saitou W, Nishimaki K, et al. Successful reintroduction of mesylate imatinib after pneumonitis in two patients with gastrointestinal stromal tumor (GIST). Nihon Kokyuki Gakkai Zasshi. 2009;47:918\u201323.","journal-title":"Nihon Kokyuki Gakkai Zasshi."},{"key":"1398_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1159\/000079633","volume":"71","author":"P Camus","year":"2004","unstructured":"Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration. 2004;71:301\u201326.","journal-title":"Respiration."},{"key":"1398_CR23","first-page":"90","volume":"95","author":"MS Tallman","year":"2000","unstructured":"Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood. 2000;95:90\u20135.","journal-title":"Blood"},{"key":"1398_CR24","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.3324\/haematol.13510","volume":"93","author":"M Breccia","year":"2008","unstructured":"Breccia M, Latagliata R, Carmosino I, Cannella L, Diverio D, Guarini A, et al. Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin. Haematologica. 2008;93:1918\u201320.","journal-title":"Haematologica"},{"key":"1398_CR25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/jnci\/djr511","volume":"104","author":"T Eisen","year":"2012","unstructured":"Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst. 2012;104:93\u2013113.","journal-title":"J Natl Cancer Inst"},{"key":"1398_CR26","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/sj.leu.2403251","volume":"18","author":"T Yokoyama","year":"2004","unstructured":"Yokoyama T, Miyazawa K, Kurakawa E, Nagate A, Shimamoto T, Iwaya K, et al. Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration. Leukemia. 2004;18:645\u20136.","journal-title":"Leukemia"},{"key":"1398_CR27","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1172\/JCI115351","volume":"88","author":"LS Snyder","year":"1991","unstructured":"Snyder LS, Hertz MI, Peterson MS, Harmon KR, Marinelli WA, Henke CA, et al. Acute lung injury: pathogenesis of intraalveolar fibrosis. J Clin Invest. 1991;88:663\u201373.","journal-title":"J Clin Invest."},{"key":"1398_CR28","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1165\/ajrcmb\/9.6.637","volume":"9","author":"J Walsh","year":"1993","unstructured":"Walsh J, Absher M, Kelley J. Variable expression of platelet-derived growth factor family proteins in acute lung injury. Am J Respir Cell Mol Biol. 1993;9:637\u201344.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1398_CR29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s12185-012-1250-3","volume":"97","author":"K Dao","year":"2013","unstructured":"Dao K, Vedy D, Lopez J, Staneczek O, Buclin T, Livio F. Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data. Int J Hematol. 2013;97:299\u2013300.","journal-title":"Int J Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-013-1398-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-013-1398-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-013-1398-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-013-1398-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:11:57Z","timestamp":1659096717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-013-1398-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,23]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["1398"],"URL":"https:\/\/doi.org\/10.1007\/s12185-013-1398-5","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,23]]},"assertion":[{"value":"20 May 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}